Autologous CIK Cells Infusion for the Treatment of Lung Cancer: a Randomized Controlled Study

Launched by THIRD MILITARY MEDICAL UNIVERSITY · Dec 22, 2011

Keywords

ClinConnect Summary

A randomized controlled trail on the efficacy and safety of autologous cytokine-induced killer (CIK) cells infusion treatment in advanced primary lung cancer

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18\~70 year old, KPS score \>50 points, estimate survival \> 3 months;
• • Primary lung cancer patients after chemotherapy or radiation therapy;
• • Primary lung cancer patients after targeted therapy;
• • Primary lung cancer patients with lung function can not accept operation or unwilling to operation;
• • Primary lung cancer recurrence or surgery can't complete resection;
• • Primary lung cancer patients after intervention therapy(I125 implanted, freezing, rf, etc.);
• • No serious mental illness and no serious heart, liver, kidney diseases, unincorporated other potentially lethal diseases;
• • Patients Voluntary attempt, and informed consent.
• Exclusion Criteria:
• • History of cardiovascular disease: congestive heart failure \> New York heart association (NYHA) level II, unstable angina patients (resting when the angina symptoms) or new happen angina pectoris (recent 3 months) or recent 6 months of myocardial infarction;
• • Cachexia; or other deadly diseases;
• • Liver function laboratory ALT, AST more than normal limits on 2.0 times ; Or kidney TBIL, BUN more than normal limits on 1.0 times , or Cr more than normal upper limit;
• • Active infection;
• • Pregnant or lactating women
• • At present Is receiving other cancer treatment (such as chemotherapy, radiation therapy, chemotherapy, immunosuppressants and thrombosis, targeted agents);
• • Now or recently will join another experimental clinical study ;
• • Other situations that the researchers considered unsuitable for this study (such as mental illness, drug abuse, HIV infections, etc.), or influence on the results of clinical trials for analysis.